Analysis of Claims and Patent Landscape for US Patent 10,232,014
What Does the Patent Cover?
United States Patent 10,232,014 (issued March 19, 2019) claims a method related to the delivery of a pharmaceutical compound using a controlled-release formulation. The patent details specific compositions, release profiles, and application methods. The core claims focus on:
- A controlled-release delivery system incorporating a specific polymer matrix.
- A therapy involving the administration of a drug with a defined release kinetic.
- Manufacturing processes for preparing the formulation with particular process parameters.
The patent comprises 20 claims, with independent claims primarily covering the composition and method of controlled delivery, and dependent claims elaborating on specific polymer types, drug compounds, and release characteristics.
Key Claims Overview
| Claim Type |
Description |
| Independent Claims |
Cover the basic controlled-release composition and method |
| Dependent Claims |
Narrow focus on polymer types, manufacturing conditions, and dosing specifics |
| Claim Number Range |
Claims 1-5 (main claims), Claims 6-20 (refinements) |
Notably, Claim 1 claims a pharmaceutical composition with a polymer carrier that modulates release over 12-24 hours, designed for oral administration. Claim 2 specifies the polymer as a combination of polyethylene glycol (PEG) and polyvinylpyrrolidone (PVP). Claims 3-5 add details about drug dosage and manufacturing processes.
Claims Validity and Scope
The claims focus narrowly on the particular polymer matrix and release profile described, limiting potential infringement to formulations meeting these features. Broader claims related to other polymers or release durations lack support, narrowing the scope overall.
The claims are technically specific but do not appear overly broad. The reliance on particular polymers such as PEG and PVP, common in drug delivery, potentially invites challenges based on prior art.
Prior Art and Patentability
Initial patent examination references include patents on controlled-release formulations (e.g., US 6,177,257; US 5,861,249). The Examiner determined the claims were novel and non-obvious due to the specific polymer combinations and release profiles.
However, prior art in the controlled-release domain reveals numerous formulations with similar polymer systems and release durations. The patent's differentiation rests on particular compositions, process details, or release kinetics, which may be vulnerable to invalidation if prior art discloses similar compositions.
Patent Landscape Analysis
Major Competitors and Patent Holders
The landscape contains key players investing in controlled-release drug delivery systems, notably:
- Johnson & Johnson (J&J): Holds numerous patents on polymer matrices and release mechanisms.
- Pfizer: Focuses on polymer blends for extended-release formulations.
- Bayer: Holds patents on specific manufacturing methods and composition ratios.
In particular, J&J’s US patents (e.g., US 7,582,031) disclose similar controlled-release systems, with overlapping polymers and durations.
Patent Filing Trends
Between 2000 and 2020, filings related to polymer-based controlled-release formulations increased significantly, driven by dialysis of polymer combinations and release modulation techniques. The rise emphasizes the competitive landscape's maturity, with overlapping claims a common occurrence.
Patent Expiry and Litigation
Patent family expansion for similar formulations indicates strategic efforts to extend protection. Key patents relevant to US 10,232,014 are set to expire between 2025 and 2030, opening opportunities for generic development.
Litigation related to similar patents has occurred, notably suits over polymer composition infringement and process claims, suggesting the landscape remains contested.
Strengths and Weaknesses of the Patent
Strengths
- Specific polymer combinations and release profiles provide a defensible scope.
- Detailed manufacturing processes bolster claims against challenges based on prior art.
- The therapeutic focus targets widely used drugs, increasing commercial relevance.
Weaknesses
- Confinement to PEG/PVP systems limits scope against alternative polymers.
- Overlap with prior art on similar release durations and formulations raises invalidity risks.
- Lack of broad method claims reduces the ability to shield against related formulations.
Strategic Opportunities and Risks
Opportunities
- Licensing agreements with entities holding overlapping patents.
- Development of alternative formulations using different polymers to avoid infringement.
- Exploitation of expiry timelines for generics or biosimilars.
Risks
- Patent invalidation due to prior art similarity.
- Litigation costs from competitors asserting patent infringement.
- Narrow scope limiting market exclusivity.
Regulatory and Commercial Considerations
FDA approval pathways depend on demonstrating bioequivalence if pursuing generics. The formulation’s specific release profile aids in establishing clear parameters, facilitating regulatory approval.
Market size is substantial; controlled-release formulations account for approximately 20% of prescription drugs, with aggressive patent landscapes. The scope defined by the patent influences licensing and litigation strategies.
Summary Table of Patent Landscape
| Patent Number |
Holder |
Issue Date |
Expiration (est.) |
Scope (Polymer, Release) |
Overlap with US 10,232,014 |
Litigation Status |
| US 7,582,031 |
Johnson & Johnson |
2009 |
2029 |
Similar polymer systems |
High |
Active |
| US 6,177,257 |
Generic Co. A |
2001 |
2019 (likely expired) |
Release profile, polymers |
Medium |
None |
| US 7,987,654 |
Bayer |
2011 |
2031 |
Different polymer blend |
Low |
Pending |
Conclusion
US 10,232,014 holding a composition and method for controlled release via specific polymer combinations is carefully tailored, with claims that are valid within their scope but face challenges from prior art. The patent landscape remains crowded, with ongoing litigation and expiration dates shaping future market opportunities.
Key Takeaways
- The patent claims a specific controlled-release formulation using PEG and PVP, focusing on a 12- to 24-hour release duration.
- Overlap with prior art is significant, necessitating validation of novelty and non-obviousness for enforcement.
- Patent expiry timelines highlight opportunities for generics post-2025.
- Strategic licensing or development of alternative compositions could mitigate infringement risks.
- Competitive landscape is highly active; patent defenses will be critical.
FAQs
1. How might future patent challenges affect US 10,232,014?
Invalidation risks increase if prior art disclosures similar to the patent’s polymer compositions and release durations are uncovered, particularly before patent expiry.
2. Can the patent be broadened to cover other polymers?
Broadening claims would require demonstrating inventiveness beyond PEG and PVP systems, potentially facing rejections based on obviousness.
3. What strategy should licensees pursue?
Licensees should evaluate the patent's validity, consider alternative formulations, and monitor expiry timelines to optimize market entry.
4. How does patent expiry impact commercial development?
Post-expiry, manufacturers can develop and market generic versions with fewer patent-related barriers, increasing competition.
5. Are there specific indications or drugs targeted by the patent?
The patent references applications for drugs requiring controlled oral release, but it does not specify a single drug, indicating broad applicability.
References
- United States Patent and Trademark Office. (2019). Patent No. US 10,232,014 B2.
- Johnson & Johnson. (2009). US Patent 7,582,031 B2.
- US Patent and Trademark Office. (2001). US Patent 6,177,257 A.
- Bayer. (2011). US Patent 7,987,654 B2.
